A Study of LY2157299 Monohydrate in Healthy Volunteers

Eli Lilly and Company8 enrolled

Overview

This study involves a single dose of 150 milligram (mg) of radiolabeled LY2157299 monohydrate in healthy participants. The study will determine how the body eliminates the radioactivity and LY2157299 monohydrate. Participants must be healthy surgically sterile or postmenopausal females, or sterile males. This study is approximately 8 to 15 days.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Healthy Volunteers

Interventions

[^14C]-LY2157299DRUG

\[\^14C\]-LY2157299 monohydrate administered as oral solution

Eligibility

Sex: ALLMin age: 21 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy surgically sterile females, postmenopausal females, or sterile males * Body mass index (BMI) of 18.5 to 32.0 kilograms per square meter (kg/m\^2) * Have venous access sufficient to allow for blood sampling Exclusion Criteria: * Have known allergies to LY2157299, related compounds or any components of the formulation * Have an abnormal blood pressure as determined by the investigator * Have participated in a \[\^14C\]-study within the last 6 months prior to admission for this study

Locations (1)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Madison, Wisconsin, United States

Outcomes

Primary Outcomes

Urinary and Fecal Excretion of LY2157299 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered

Time frame: Pre-dose through Day 15